Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
Public ClinicalTrials.gov record NCT02514447. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28), a Cyclin Dependent Kinase (CDK) 4/6 inhibitor, in preserving the bone marrow and the immune system, in order to decrease chemotherapy-induced myelosuppression and improve anti-tumor efficacy when administered prior to topotecan in patients previously treated for extensive-stage SCLC. The study consisted of 2 parts: a limited open-label, dose-finding portion (Part 1), and a randomized double-blind portion (Part 2). Both parts included 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase began on the day of first dose with study treatment and completes at the Post-Treatment Visit.
Study identification
- NCT ID
- NCT02514447
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 123 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 4, 2015
- Primary completion
- Sep 27, 2018
- Completion
- Oct 3, 2021
- Last update posted
- Sep 24, 2025
2015 – 2021
United States locations
- U.S. sites
- 35
- U.S. states
- 17
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Genesis Cancer Center | Hot Springs | Arkansas | 71913 | — |
| Highlands Oncology Group | Rogers | Arkansas | 72758 | — |
| Compassionate Cancer Care Medical Group, Inc. | Corona | California | 92879 | — |
| Sutter Medical Group | Sacramento | California | 95816 | — |
| The Oncology Institute of Hope and Innovation | Whittier | California | 90603 | — |
| Memorial Hospital - University of Colorado Health | Colorado Springs | Colorado | 80909 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| University of Colorado Health, Oncology Clinical Research Northern Region | Fort Collins | Colorado | 80528 | — |
| Florida Cancer Specialists - South | Fort Myers | Florida | 33916 | — |
| Florida Cancer Specialists - North | Tavares | Florida | 32778 | — |
| University Cancer and Blood Center, LLC | Athens | Georgia | 30607 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Northside Hospital - Georgia Cancer Specialists | Atlanta | Georgia | 30341 | — |
| Saint Luke's Cancer Institute | Kansas City | Missouri | 64111 | — |
| Norris Cotton Cancer Center | Lebanon | New Hampshire | 03756 | — |
| North Shore Hematology Oncology Associates PC | East Setauket | New York | 11733 | — |
| Regional Medical Oncology Center | Wilson | North Carolina | 27893 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Oklahoma University - Peggy and Charles Stephenson Cancer Center | Oklahoma City | Oklahoma | 73117 | — |
| Guthrie Medical Group, PC | Sayre | Pennsylvania | 18840 | — |
| AnMed Health | Anderson | South Carolina | 29621 | — |
| Greenville Health System | Greenville | South Carolina | 29605 | — |
| Gibbs Cancer Center | Spartanburg | South Carolina | 29303 | — |
| Hanna Cancer Associates - University of Tennessee | Knoxville | Tennessee | 37920 | — |
| Meharry Medical College | Nashville | Tennessee | 37208 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37232 | — |
| Texas Oncology- Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| M.D. Anderson | Houston | Texas | 77030 | — |
| Millennium Oncology | Houston | Texas | 77090 | — |
| Southwest Cancer Center | Lubbock | Texas | 79415 | — |
| Texas Oncology | Tyler | Texas | 75702 | — |
| The University of Texas Health Science Center at Tyler | Tyler | Texas | 75708 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Northwest Cancer Specialists, P.C. | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02514447, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2025 · Synced Sep 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02514447 live on ClinicalTrials.gov.